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Abstract
A Symposium regarding the Pathophysiology of Successful and Unsuccessful Ageing was held in Palermo, Italy
between April 7 and 8
th 2009. Here the lecture by Sikora with some input from the chairpersons Scapagnini and
Barbagallo is summarized. Ageing is manifested by the decreasing health status and increasing probability to
acquire age-related disease such as cancer, Alzheimer’s disease, atherosclerosis, metabolic disorders and others.
They are likely caused by low grade inflammation driven by oxygen stress and manifested by the increased level of
pro-inflammatory cytokines such as IL-1, IL-6 and TNF-a, encoded by genes activated by the transcription factor
NF-B. It is believed that ageing is plastic and can be slowed down by caloric restriction as well as by some nutra-
ceuticals. Accordingly, slowing down ageing and postponing the onset of age-related diseases might be achieved
by blocking the NF-B-dependent inflammation. In this review we consider the possibility of the spice curcumin, a
powerful antioxidant and anti-inflammatory agent possibly capable of improving the health status of the elderly.
Background
A Symposium regarding the Pathophysiology of Success-
ful and Unsuccessful Ageing was held in Palermo, Italy
between April 7-8
th 2009. Comments and keynotes by E.
Sikora, G. Scapagnini and M. Barbagallo are summarized
here.
Ageing and age-related diseases
The ageing process, opposite to longevity, is not geneti-
cally programmed. There are no genes that have been
selected to actually promote ageing. The theory of evo-
lution assumes that there is a trade-off between body
maintenance and investment in reproduction [1]. Life-
span is regulated by genes controlling the activity of
metabolism, antioxidant systems, DNA repair, cellular
senescence and cell death. Their functions gradually
decline due to random errors in DNA replication and
damage to macromolecules, what leads to the accumula-
tion of senescent cells and damaged tissue with age.
However, diverse tissues building various organs may
show different patterns of senescence [2-4]. The lesions
accumulating with age are mainly, but not exclusively,
caused by the increasing level of reactive oxygen species
(ROS), as originally proposed by Harman [5].
A key in the ageing of an organism is immunosenes-
cence which may play a part in the age-related immuno-
logical changes [6]. Lifelong exposure to a plethora of
antigens (bacterial, viral, exogenous, auto, which can be
considered as stressors) leads to a gradual decline of
naive T cells. In turn, there is an accumulation of mem-
ory T and effector CD8+CD28- T cells which secrete
increased amounts of pro-inflammatory cytokines [7].
Another major consequence of chronic exposure to
antigens is the progressive activation of macrophages
and related cells in most organs and tissues of the body
creating an imbalance between inflammatory and anti-
inflammatory networks. This results in the low grade
chronic pro-inflammatory status (inflamm-ageing) [6].
Inflamm-ageing can be characterized by an increased
level of a variety of pro-inflammatory cytokines in tis-
sues, and other inflammatory markers, such as coagula-
tion cascade components, and the presence of viral
infections caused by the following viruses: CMV and
Epstein Barr virus (EBV) [8]. Cellular participants in
low-grade inflammatory status not only include cells of
the immune sytem but also other ones which have
undergone genotoxic stress-induced senescence and
secrete many inflammatory cytokines, to the so-called
senescence-associated secretory phenotype (SASP) [9].
Ageing, although not a disease by itself, makes the
organism vulnerable to a plethora of them. Holliday
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guished from age-related diseases [10]. Indeed, it seems
that many age-related pathologies share the signalling
pathways with the process of ageing. It has been pro-
posed that low-grade inflammation may not be the
cause of ageing itself (inflamm-ageing and SASP), but
also of many age-related diseases [11-13].
Several lines of evidence have led to the general
acceptance of a link between inflammation and cancer.
Generally, cancer and inflammation are connected by
two pathways: the intrinsic and the extrinsic one. The
intrinsic pathway means that oncogene activation
induces in transformed cells the production of inflam-
matory mediators, mainly via the activation of the tran-
scription factor NF-B. Conversely, in the extrinsic
pathway inflammatory or infectious conditions augment
the risk of cancer development. Epidemiological studies
have shown that chronic inflammation predisposes indi-
viduals to various types of cancer [14]. Recently inflam-
mation has been proposed as the seventh feature of
cancer [15] which should be added to the six canonical
previously proposed ones [16].
Inflammation is also considered to be a critical initial
step in the development of atherosclerosis [13]. The
early phase of atherogenesis is characterized by the
attraction/adherence of monocytes to the vascular
endothelium and their migration into the vessel wall.
The expression of cellular adhesion molecules promotes
the adhesion of leukocytes to the vascular endothelium
and is induced by inflammatory factors, including IL-1,
TNF-a, and CRP. Furthermore, the progressive accumu-
lation of macrophages and their uptake of oxidized LDL
ultimately leads to the generation of the so called foam
cells and initiation of fatty streaks [12]. It seems that
NF-B is the main mediator of inflammation and
endothelial dysfunction in the elderly [17].
An inflammatory state has been documented in senile
plaques and surrounding glia with an increased expres-
sion of the acute phase protein CRP as well as pro-
inflammatory interleukins such as IL-6 and IL-1 in Alz-
heimer’s disease (AD) patients and animal models [18].
The evidence of inflammatory mechanisms being
involved in AD is also based on the fact that certain
anti-inflammatory drugs could modify the course of the
disease [19,20].
Obesity, insulin resistance and type 2 diabetes are also
closely associated with chronic inflammation. Exposure
to excess amounts of nutrients and energy can reactivate
the ancient inflammatory potential of metabolically
important tissues. The adipose tissue of obese indivi-
duals has in fact been shown to produce higher levels of
the pro-inflammatory cytokines (TNF, IL-6) and other
pro-inflammatory factors [21].
The assumption of a link between ageing and age-
related diseases raises the pivotal question of whether
concentrating the effort on just curing the age-asso-
ciated diseases is the optimal approach to making our
later lives more healthy and comfortable. Indeed, a new
strategy hopefully leading to healthy ageing has been
proposed. Recently, it has been postulated that interven-
tions aimed at slowing down ageing could offer a much
greater benefit than those targeted at individual diseases
[22]. The evolutionary theory of disposable soma sug-
gests that ageing is unavoidable but malleable and plas-
tic [23] and perhaps this may be possible by dietary or
pharmaceutical intervention or genetic alteration, to
extend the lifespan [22].
Curcumin as an anti-inflammatory agent
Nutraceuticals are food ingredients which either have a
proven physiological benefit or provide protection
against chronic diseases. They may contribute to the
prevention of diseases and ageing. Diet has a major role
in modulating the risk of development of several dis-
eases and successful ageing. Edible plants, amongst diet-
ary constituents, are important in that they contain
phytochemicals which can control biochemical processes
at cellular level of animal organism.
Among nutraceuticals, the role of curcumin is sup-
ported by a number of scientific evidence that have con-
firmed its anti-inflammatory and anti-oxidant actions
both in vivo and in vitro. Curcumin is the phytochem-
ical derived from the rhizome of Curcuma longa,p r e -
sent in the spice turmeric and it gives Indian curry its
yellow color. Curcumin has been used for millennia as a
wound-healing agent and for treating a variety of dis-
eases in traditional Indian and Chinese medicine.
Recently, it has attracted the attention of researchers as
an agent capable of inhibiting the proliferation of cancer
cells and/or inducing many signaling pathways leading
to various modes of cell death [24,25]. As a cell death
inducer curcumin has gained profound interest as a che-
mopreventive and anti-cancer agent which found confir-
mation in many in vitro experiments and preclinical
studies on animal models.
Furthermore curcumin rises interest as an agent of
potential use in therapy of many diseases (not only can-
cer) with an inflammation constituents including cardio-
vascular diseases, Alzheimer’s disease, rheumatoid
arthritis and metabolic syndrome. Although only a few
worldwide clinical trials are underway now [26], a
plethora of studies using animal and cell line models
have been undertaken to elucidate the molecular
mechanisms and biological effects of curcumin.
Curcumin has an unprecedented number of molecular
targets justifying its chemopreventive, antioxidant and
anti-inflammatory activities (reviewed recently in
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tors with AP-1 described as the first one, and others
s u c ha sS P - 1 ,p 5 3 ,S T A T - 3 ,A T F 3 ,N r f 2 ,P P A R - g,
CHOP, HIF-1a, b-catenin and NF-B, enzymes such as
protein kinases (PKA, PKC, FAK, Src), glutathione S-
transferase, DNA topoisomerase-II, telomerase, heme-
oxygenase-1, p300 histone acetyltransferase, metalopro-
teinases, lipoxygenase (5-LOX), cyclooxygenase-2 (COX-
2) and others. The most far-reaching physiological con-
sequences seem to stem from the action of curcumin as
an inhibitor of the activity of the transcription factor
NF-B. The NF-B transcription factor is a master reg-
ulator of the inflammatory process which activates the
expression of many pro-inflammatory cytokines, such as
TNF-a,I L - 1 b and IL-6. Some of the NF-B-induced
proteins, like TNF-a, are also its activators, which is
particularly important in the chronic inflammatory state.
NF-B seems to be the culprit of inflammageing, since
this signaling system integrates the intracellular regula-
tion of immune responses in both ageing and age-
related diseases [29].
Many activities of curcumin can be also explained by
its ability to suppress acute and chronic inflammation
by scavenging reactive oxygen and reactive nitrogen spe-
cies and enhancing antioxidant defense (i.e. by increas-
ing glutathione level). However, curcumin is not only a
simple antioxidant, but as a electrophilic compound it
triggers the Nrf2/ARE signaling pathway which plays a
key role in activating antioxidative enzymes, phase 2
enzymes and so - called vitagens (heme oxygenase,
Hsp70, thioredoxin reductase and sirtuins), which might
have a pivotal role in oxidative stress-induced diseases
[30].
T h ea m o u n to fd a t ad o c u m e n t i ng beneficial effects of
curcumin in protecting against different diseases, parti-
cularly those which are related to age are increasing. It
seems that extraordinary potency of curcumin, which
makes it an almost universal remedy, results from the
inflammatory origins of many diseases and curcumin’s
anti-inflammatory activity.
Despite the practical lack of data showing curcumin’s
influence on ageing and lifespan, there is a strong
rational argument suggesting that curcumin can influ-
ence the process of senescence and ageing retardation
[25].
Curcumin and AD
Recently curcumin has been proposed as a potential
remedy against brain ageing and neurodegenerative dis-
orders [31], and it has been evaluated in a pilot clinical
trial in AD patients, with encouraging preliminary
results [32]. Curcumin is highly lipophilic and might
cross the blood-brain barrier (BBB) to reach the brain.
Although its bioavailability is very low, since the drug is
rapidly metabolized by conjugation, curcumin may
reach brain in a sufficient concentration to activate sig-
nal transduction events and to decrease Ab aggregation
[33]. Epidemiological studies suggested that curcumin,
one of the most prevalent nutritional and medical com-
pounds used by the Indian population, is responsible for
the significantly reduced (4.4-fold) prevalence of AD in
India compared to United States [34]. Furthermore
elderly Singaporeans who ate curry with turmeric had
higher Mini-Mental State Examination scores than those
who did not [35].
Conclusions
Curcumin can counteract the pro-inflammatory state
which is believed to participate in many age-related dis-
eases. In fact, it seems that curcumin directly affects a
few major targets, just like ROS scavenging and produc-
tion and the NF-B signaling pathways, which can in
turn suppresses the pro-inflammatory state involved in
the etiology of ageing and age-related diseases.
The main concern regarding the therapeutic value of
curcumin is its poor bioavailability, which, on the other
h a n d ,a s s u r e sl a c ko ft o x i c i t ye v e nw h e nc o n s u m e di na
daily dose of 8 mg. Moreover, the data so far collected,
show that curcumin has a very high activity not only in
in vitro experiments, but also at the organismal level.
This could be explained by its hormetic activity [36].
Accordingly, it appears that curcumin is a very safe and
beneficial nutraceutical spice which might fend off age-
ing and age-related diseases. However, at this time there
is no data showing that any nutraceutical may influence
ageing and lifespan, and complete randomized clinical
trials in humans are also needed to confirm the poten-
tial use of curcumin in the prevention of diseases with
an inflammation constituents,e . g .c a r d i o v a s c u l a rd i s -
eases, AD, cardiometabolic syndrome, and ageing.
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